U.S. Markets closed

OPKO Health, Inc. (OPK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.5500+0.0300 (+0.66%)
At close: 4:00PM EST
Sign in to post a message.
  • J
    Jacek
    Guys, please listen the yesterday $OPK presentation at J.P. Morgan in quiet.
    To all upfront $OPK and dr, Frost critics... try to understand... that $OPK has fantastically expanded their lab, diagnostics and scientific capabilities.
    That all requires massive investment.. which must not be directly comparable to the revenue from COVID testing.
    But all of these investments will pay back withing next 2-3 years massively.

    Since I work on pharma deployments I know how demanding and costly all this is...and the most important is the personal potential of newly trained staff and new executives (mentioned in the presentation).

    So we should expect return on these investments 2H 2021 onwards.

    I estimate the share price of $OPK.. based on revenue v.s. all-in (direct & hidden in personal development) investment as: $8,30 - $9,60 by the end of 2Q 2021, $10,80 - $12,00 by the end of 4Q 2021, and $16,00 -$20,00 mid 2022.

    Happy trading, Guys :)
  • m
    malcolm
    New stimulus package proposal has huge dollars for testing AND big city bailouts. Could not be a better mix for the company doing the NYC school testing. Little mention of their possible drug products recently. These could ignite 2nd stage rocket acceleration.
  • S
    Steve
    We all know they are shorting this down for options. The good news is that they HAVE to short it to stop the rising stock price. Slow and steady ..... each Friday will be a higher and higher max pain option price. Eventually stock price will get to where it belongs and all of these mms and shorts playing games will get burned.
    Bullish
  • P
    Pete
    Bottom line - They concluded by saying they expect to exceed fourth quarter guidance on both revenues and profits. Other notes include: demand for the covid testing business continues to experience strong growth and they expect it will continue to do so throughout 2021 in order to be able to open up our economy. The other parts of the testing business are also doing very well and it sounds like Rayaldee, Somatrogon and drug development business doing well too. I'd say very good news but who knows how it will affect the share price.
  • m
    marc
    Any reasonable and fundament reason to be short this stock is disappearing quickly.
  • L
    Lookingforatenbagger
    From the J. P. Morgan transcript: Logal: "I'll mention that our Q3 revenue were up over $428 million, essentially a doubling of our 2019 revenues. And as we had – as Jon mentioned, we did a significant number of tests, PCR test for COVID this quarter, which exceeded our previously issued guidance, and we're pleased to say that we will exceed our previous guidance and confirming our revenue guidance.

    We were profitable in the third quarter and also guided for profitability in the fourth quarter of this year. And considering both of those expect a full year profitability for the company."

    https://seekingalpha.com/article/4398830-opko-health-inc-opk-ceo-phil-frost-presents-39th-annual-jpmorgan-virtual-healthcare
  • S
    Sir
    I bought a bunch more because I believe that OPK is going to generate a lot of buyout and partnership interest from big pharma with deep pockets due to their positive revenue stream, quality testing, potential of other products like covid or other meds. Not too many companies operating in the black from the effects of the pandemic all of last year.
  • L
    Lookingforatenbagger
    Boo Bird Frankie wrote just two weeks ago, when the PPS was UNDER $4. "@Mike as I said the stock goes up when shorts decide"
    LFTB: I guess the shorts decided it was time to go up 15%.
  • n
    norman
    Another Friday, it will be interesting to see if the share price holds above the $4.50 per share, making call options in the money. MMs have been successful the last few weeks, but we have $50 billion being budgeted for testing and a good JPM conference.

    I am optimistic that the price closes above $4.50 and maybe takes out the resistance @$ 4.60.
    Bullish
  • L
    Lookingforatenbagger
    Ravi asks, "When is the OPKO earnings date for this Quarter? "
    Since it the end of the physical year the have 60 days after the end of the fiscal year. They can report anytime they wish, within the 60 day period. In 2020 they reported on February 26th. By my calculations they could report as late as March 1st, 2021.
  • J
    J
    Earlier today I began the early stages of getting concerned about the outlook for this stock. The reason is that the market is always forward looking and all indices are up significantly of late. That being said OPK has done well given their 3Q results and outlook and with increased testing since then the only conclusion is that the 4Q will be even better. Why hasn't the market recognized this? If the markets are forward looking shouldn't the price be accelerating? I haven't seen anything materially negative about this stock since before the pandemic. Your thoughts.....(please, serious replies only).
  • m
    marc
    Fundamentals, balance sheet and outlook are far better than 12 months ago. To get the stock moving we could use an analyst comment from JPM, but more importantly the buy back of the convertible. OPK should have the means in Q2 of 2021 to accomplish this
  • g
    greg
    If OPKO’s Q4 guidance was conservative, and they in fact substantially exceed their projections, that would be a good thing. Why would you want to own stock in a company whose management provides pie in the sky projections, only to later have to make excuses. Under promise (be conservative) and over deliver is the right way!
  • P
    Pete
    Forgot to call out new Scarlet Health at home testing venture. At home testing could be a huge business and if they can do it well it could be great for their business. Based on what I've seen so far Jon Cohen is someone I'd choose to lead such an effort.
  • L
    Lookingforatenbagger
    Boo Bird Frankie wrote yesterday after the close, "So reading posts ... dead money until 3rd qt. Stays trading 3.50-4.50"
    LFTB: Well looks like that bold prediction lasted about 16 hours. Opened at $4.62 and trade in the range $4.54 to $4.77.
  • J
    Josef
    I am in at $3.96 since last heavy purchase of Frost.... I do not complain, I do not see a problem in return of investment, and I am here becasue I see this stock goes to $10, because IT MAKES MONEY...
    you may not like it, you can write opposite....but that is all you can do... :-)
    OPKO to $10!!!
  • d
    doni
    Opko Health expects to beat its guidance for PCR tests for Covid in 4Q
    Stocks mentioned: OPK
    Share
    Listen
    Save
    Opko Health (NASDAQ:OPK) expects to beat its previously issued guidance for PCR tests for Covid-19 for 4Q and confirmed its revenue guidance, CFO Adam Logal said earlier at the JPMorgan Healthcare conference.
    Logal said Opko was profitable in 3Q and also guided for profitability in 4Q and expects a full year profitability, according to transcript of the conference.
    Earlier, Sian Capital urges OPKO Health to address apparently misleading 4Q’20 guidance.
    Also earlier, OPKO Health's subsidiary introduces Scarlet Health in-home diagnostic service.
    Recall Oct. 28, Opko pushed by Sian to conduct review, possible sale.
    Link to original article
  • n
    norman
    If Sian was really interested in increasing the share price they would not have issued their letter. They would have waited for earnings to be released and if there was a big surprise beat, the share price would increase dramatically. Of course, that is not Sian's objective.

    When it comes to earnings announcements, there has always been official announcements and "whisper" earnings projections. Fly On The Wall was a site that used to publish such information. I am not sure if they are still around.
    Bullish
  • A
    Arturo
    First of all, I would like the communication or response, if there is one, to be in a respectful tone, which is not abundant in this forum. Second, I have been an investor in this company for more than 10 years. I won when I bought at $ 1 and it reached 19 but I was too greedy and bought back at 16 when it was not rational to do so. I lost a lot with options and today I have 100k shares an average of about 8 dollars. Fortunately, other investments have allowed me to maintain my position even today because I believe that this company is undervalued. It is undeniable that the participation of the command of this company in press conferences has not had positive results for the value of its shares. They have not had good advice when it comes to their way of communicating. @lookingforatenbagger accuses me of Bo bird (I don´t know what this mean) for making it noticed today. On this day, the OPK team led by Frost, succumbed to Siam's provocation and acknowledged that their numbers would be above projections. What benefit did it produce? less than 2% in the PPS appreciation. However, this itself produces less surprise when it comes to giving the earnings for the quarter and raises expectations to numbers that will be very easy to disappoint when too much is expected as it was in the previous quarter. Was this smart? I don´t know, time will tell. It has been a long time since the good news in the company does not bring as a corollary a proportional increase in its share price. So: isn't it time to change the marketing strategy? I still believe in the possibilities of the company but I believe that like a discredited politician, his life depends on a good image consultant. That should be the top hire this year. The company is doing well but communicates very poorly
    Bullish
  • j
    joseph
    OPK presents tomorrow afternoon at JP Morgan conference, which means they will probably be putting out a press release with new-news tomorrow morning to allow them to legally expand on it during there presentation, so ...... I'm in for a bit more this morning.